Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.14 USD
Change Today +0.01 / 0.08%
Volume 10.5K
As of 9:50 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

heron therapeutics inc (HRTX) Snapshot

Open
$12.15
Previous Close
$12.13
Day High
$12.22
Day Low
$12.01
52 Week High
03/20/15 - $16.49
52 Week Low
10/13/14 - $6.51
Market Cap
359.7M
Average Volume 10 Days
312.7K
EPS TTM
$-2.83
Shares Outstanding
29.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HERON THERAPEUTICS INC (HRTX)

Related News

No related news articles were found.

heron therapeutics inc (HRTX) Related Businessweek News

No Related Businessweek News Found

heron therapeutics inc (HRTX) Details

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company’s lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

59 Employees
Last Reported Date: 03/13/15
Founded in 1983

heron therapeutics inc (HRTX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $540.8K
President, Chief Commercial Officer and Direc...
Total Annual Compensation: $540.8K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $285.0K
Senior Vice President of Technical Operations
Total Annual Compensation: $395.0K
Compensation as of Fiscal Year 2014.

heron therapeutics inc (HRTX) Key Developments

Heron Therapeutics Announces Positive Outcome from Meeting with FDA for HTX-019

Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's proposal to use the 505(b)(2) development pathway for HTX-019, Heron's proprietary intravenous formulation of aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV). A 505(b)(2) application allows a portion of the information required for a New Drug Application (NDA) approval, such as safety and efficacy data on the active ingredient, to come from previously completed studies conducted by other parties. This pathway can lead to significantly reduced costs and time required for development compared with a traditional development path.

Heron Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Heron Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net loss was $20.6 million, or $0.70 per share, compared to a net loss of $17.5 million, or $0.74 per share, for the same period in 2014. The increase in net loss was primarily due to costs associated with the Company’s recently completed Phase 1 clinical study for HTX-011 and costs for the ongoing Phase 3 HEC study for SUSTOL. The decrease in net loss per share for the three months ended March 31, 2015 compared to the same period in 2014 was mainly due to the increase in shares outstanding as a result of the company’s June 2014 common stock offering, partially offset by the increase in net loss. Loss from operations was $20.36 million compared to $17.32 million reported a year ago.

Heron Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 11:20 AM

Heron Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 11:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Barry D. Quart, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HRTX:US $12.14 USD +0.01

HRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.46 USD +0.64
Foamix Pharmaceuticals Ltd $13.00 USD +0.41
Johnson & Johnson $101.14 USD +0.318
Pacira Pharmaceuticals Inc/DE $77.68 USD +0.66
Sanofi €92.16 EUR +1.52
View Industry Companies
 

Industry Analysis

HRTX

Industry Average

Valuation HRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HERON THERAPEUTICS INC, please visit www.herontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.